Ichnos is also exploring partnerships for ISB 830 (telazorlimab), a tumor necrosis factor receptor superfamily member 4 (OX40) antagonist monoclonal antibody that successfully completed a phase 2b ...

In the context of AD, OX40, a costimulatory receptor present on activated T cells, supports the function of inflammatory T cells, exacerbating skin dysfunction. Researchers from Astria Therapeutics ...

In January, Sanofi agreed a $1.45 billion deal to acquire UK biotech Kymab and its lead drug KY1005, an OX40 antibody that like KHK4083 has already cleared a phase 2 trial in atopic dermatitis.

APVO603 is a novel bispecific antibody designed to enhance anti-tumor immune responses through dual targeting of 4-1BB (CD137) and OX40 (CD134), two key co-stimulatory receptors involved in T cell ...

The data drops provide more evidence that the Kyowa Kirin-partnered rocatinlimab improves outcomes in atopic dermatitis, but questions about the positioning of the anti-OX40 antibody versus Sanofi ...